Overview
Knowledgeable and experienced site investigators are vital to conducting efficient, high-quality clinical trials. However, issues like heavy workload and extensive time requirements are contributing to a high rate of investigator turnover and driving some researchers away from clinical trials altogether. If left unchecked, this trend could threaten the overall quality and efficiency of clinical research.
CTTI’s recommendations address these many issues, giving CROs, sponsors, health systems, investigators, and others ways to create a better research environment that sustains long-term engagement and fosters improved quality and efficiency in clinical trials.
Solutions
Search AllRecommendation Summary
Recommendations
Resources
Related Items
- Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials
- Improving and sustaining the site investigator community: Recommendations from the Clinical Trials Transformation Initiative
- CTTI Presents Recommendations for Strengthening the Investigator Site Community
- CTTI Takes on Site Investigator Turnover in New Recommendations
- Strengthening the Investigator Community Project
- One and done: Reasons principal investigators conduct only one FDA-regulated drug trial
- Investigator Training Efficiencies Highlighted in New CTTI GCP Recommendations
News
- CTTI Article Uncovers Why Principal Investigators Conduct Multiple FDA-Regulated Drug TrialsBuilding on a previous study on the reasons why principal investigators conduct only one FDA-regulated drug trial (“one-and-done” investigators), a new CTTI article published in Contemporary Clinical Trials Communications explores the converse: barriers and ...